Live
- A Guide to Temperature and Humidity Standards in Data Center Server Rooms
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Sun Pharma wraps up acquisition of InSite Vision
Drug major Sun Pharmaceutical Industries on Tuesday said it has completed acquisition of US-based eye care firm InSite Vision.
New Delhi : Drug major Sun Pharmaceutical Industries on Tuesday said it has completed acquisition of US-based eye care firm InSite Vision.
The acquisition was completed by means of a short-form merger under the Delaware law, Sun Pharma said in a statement. Post-merger, InSite Vision has become an indirect wholly-owned subsidiary of Sun Pharma.
The company in September had announced its plan to acquire InSite Vision for around $48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the US.
The company said "each issued and outstanding share of InSite common stock... was converted into the right to receive $0.35 as a result of the merger". InSite will no longer have reporting obligations under the Securities Exchange Act of 1934 as amended.
